Disregulated Wnt/β-catenin signaling has been linked to various human diseases, including cancers. Inhibitors of oncogenic Wnt signaling are likely to have a therapeutic effect in cancers. LRP5 and LRP6 are closely related membrane coreceptors for Wnt proteins. Using a phage-display library, we identified anti-LRP6 antibodies that either inhibit or enhance Wnt signaling. Two classes of LRP6 antagonistic antibodies were discovered: one class specifically inhibits Wnt proteins represented by Wnt1, whereas the second class specifically inhibits Wnt proteins represented by Wnt3a. Epitope-mapping experiments indicated that Wnt1 class-specific antibodies bind to the first propeller and Wnt3a class-specific antibodies bind to the third propeller of LRP6, suggesting that Wnt1-and Wnt3a-class proteins interact with distinct LRP6 propeller domains. This conclusion is further supported by the structural functional analysis of LRP5/6 and the finding that the Wnt antagonist Sclerostin interacts with the first propeller of LRP5/6 and preferentially inhibits the Wnt1-class proteins. We also show that Wnt1 or Wnt3a class-specific anti-LRP6 antibodies specifically block growth of MMTV-Wnt1 or MMTV-Wnt3 xenografts in vivo. Therapeutic application of these antibodies could be limited without knowing the type of Wnt proteins expressed in cancers. This is further complicated by our finding that bivalent LRP6 antibodies sensitize cells to the nonblocked class of Wnt proteins. The generation of a biparatopic LRP6 antibody blocks both Wnt1-and Wnt3a-mediated signaling without showing agonistic activity. Our studies provide insights into Wnt-induced LRP5/6 activation and show the potential utility of LRP6 antibodies in Wntdriven cancer.
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antibody therapeutics | cancer T he Wnt/β-catenin pathway regulates diverse biological processes during development and tissue homeostasis by modulating the protein stability of β-catenin (1-3). In the absence of extracellular Wnt proteins, cytoplasmic β-catenin is associated with the β-catenin destruction complex and degraded by ubiquitinmediated proteolysis. Wnt signals are transduced by two distinct receptors, the serpentine receptor Frizzled (Frz) and the singlespan transmembrane proteins LRP5 or LRP6. Wnt proteins promote the assembly of the Frz-LRP5/6 signaling complex and induce phosphorylation of LRP5 or LRP6. Phosphorylated LRP5 or LRP6 inactivates the β-catenin degradation complex, allowing stabilized β-catenin to enter the nucleus, bind to the TCF transcription factors, and act as a transcriptional coactivator.
The extracellular domain of LRP5 or LRP6 contains four YWTD-type β-propeller domains each followed by an EGF-like domain and an LDLR domain. Each propeller contains six YWTD motifs that form a six-bladed β-propeller structure (4) . Biochemical studies suggest that Wnt proteins physically interact with both Frz and LRP6 and induce the formation of an Frz-LRP6 signaling complex (5, 6) . Experimentally induced proximity of Frz and LRP6 is sufficient to activate Wnt signaling (7) (8) (9) . In addition to Wnt proteins, the large extracellular domain of LRP5 or LRP6 binds to multiple secreted Wnt modulators, including the Wnt antagonists DKK1 and Sclerostin (SOST), and the Wnt agonists R-Spondins. Existence of natural secreted modulators of LRP5/6 and mutations of LRP5/6 in various human diseases points to the possibility of using LRP5/6 antibodies to modulate Wnt signaling in disease settings (10) (11) (12) .
Disregulation of the Wnt-signaling pathway has been linked to cancer. Mutations in pathway components such as APC and β-catenin have been associated with a number of human cancers, and recent studies suggest that overexpression of Wnt proteins and/or silencing of Wnt antagonists such as DKK1, WISP, and sFRPs may promote cancer development and progression (13) (14) (15) (16) . In addition, Wnt signaling plays a critical role in the homeostatic regulation of tissue stem cells and hence, is implicated in the maintenance of cancer stem cells (17, 18) . These data suggest that antagonists of Wnt signaling might be used in the treatment of Wnt-dependent cancers.
Wnt signaling also plays important roles in tissue homeostasis and regeneration. Wnt signaling promotes bone formation by increasing the growth and differentiation of osteoblasts (19) , and in humans, gain-of-function mutations of LRP5 (10, 20) and lossof-function mutations of Wnt antagonist SOST (21, 22) lead to high bone-mass diseases. Wnt signaling is also critical for the homeostasis of the intestinal epithelium by maintaining the proliferative status of stem cells in the intestinal crypt (23) . Agents that sensitize cells to Wnt signaling might be used to treat bone or intestinal disorders such as osteoporosis and mucositis.
To discover antibody modulators of Wnt signaling, we generated both antagonistic and agonistic antibodies directed against LRP6. Using these antibodies, we find that distinct propellers of LRP6 are differentially required for the signaling activities of different Wnt proteins. These findings provide insights into the mechanism of Wnt-induced LRP5/6 activation and show the utility of LRP6 antibodies that inhibit Wnt signaling in cancer.
Results

Identification of Anti-LRP6 Fab Fragments That Specifically Inhibit
Wnt1-or Wnt3a-Induced β-Catenin Signaling. To identify LRP6 antibodies modulating Wnt signaling, HEK293 cells overexpressing a GFP-tagged intracellular domain-truncated LRP6 (LRP6ΔC-GFP) or recombinant proteins of the extracellular domain of LRP6 were used for panning with the HuCAL GOLD phagemid library. Fab fragments with activity in LRP6-binding assays were tested for the ability to modulate Wnt1-or Wnt3a-induced SuperTopFlash (STF) reporter. Surprisingly, all antagonistic anti-LRP6 Fab fragments could be grouped into two distinct classes, class A and class B. Fab fragments of class A, represented by A1, A2, A3, A4, A5, and A6, strongly inhibited Wnt1-induced STF without affecting Wnt3a-induced STF (Fig. 1A) . Fab fragments of class B, represented by B1, B2, B3, and B4, strongly inhibited Wnt3a-induced STF without affecting Wnt1-induced STF (Fig. 1A) . In addition, Fab fragments of each class displayed the same differential inhibition of Wnt1-or Wnt3a-induced LRP6 phosphorylation in HEK293 cells (Fig. 1B) .
We next sought to determine whether β-catenin signaling induced by diverse Wnt proteins was differentially affected by Wnt1-or Wnt3a-specific anti-LRP6 Fab fragments. There are 19 Wnt proteins in the human, and at least 10 of them can activate β-catenin signaling and the STF reporter in HEK293 cells with or without coexpression of Frz receptors. In these Wnt-driven STF assays, Wnt proteins can be grouped into two classes (Fig. 1C) . One class of Wnt proteins, including Wnt1, Wnt2, Wnt6, Wnt7a, Wnt7b, Wnt9a, Wnt10a, and Wnt10b, was specifically inhibited by Wnt1-specific anti-LRP6 Fab fragments (A1-Fab and A2-Fab). The other class of Wnt proteins, including Wnt3 and Wnt3a, was specifically inhibited by Wnt3a-specific anti-LRP6 Fab fragments (B2-Fab and B3-Fab). Multiple lines of evidence suggest that Wnt proteins trigger downstream signaling by physically interacting with both Frz and LRP5/6. Hence, these data strongly suggest that different Wnt proteins bind to distinct regions of LRP6.
Characterization of Monovalent Agonistic LRP6 Antibodies. In addition to the two classes of antagonistic LRP6 antibodies described above, we also identified a class of agonistic LRP6 antibodies (class C). Two anti-LRP6 Fab fragments (C1-Fab and C2-Fab) did not affect STF reporter without exogenous Wnt proteins but increased Wnt3a-induced STF activation ( Fig. 2A) and Wnt3a-induced LRP6 phosphorylation (Fig. 2B ). Using analytical sizeexclusion chromatography, we found that both C1-Fab and C2-Fab were over 99% monomer (Fig. S1 ). Therefore, it is unlikely that these Fab fragments form protein aggregates and sensitize cells to Wnt signaling through dimerization of LRP6. Indeed, C1 in the IgG format had a similar, not stronger, stimulating activity than in the Fab format on Wnt3a-induced expression of Axin2, a β-catenin target gene (Fig. 2C) . Furthermore, this class of antibodies increased both Wnt1-and Wnt3a-mediated signaling (Fig. 2D ). Because C1 and C2 bind to the same region of LRP6 (Discussion), they likely increase Wnt signaling through a specific mechanism, possibly by relieving an inhibitory conformation of LRP6.
Propeller 1 and Propeller 3 of LRP5/6 Are Differentially Required for
Wnt1-and Wnt3a-Mediated Signaling. To characterize the binding domains of the three classes of LRP6 antibodies identified in this study, we performed FACS-based cross-competition experiments by testing the binding of biotinylated Fab fragments to ectopically expressed LRP6 in an excess of unbiotinylated competing Fab fragments. We found that antibodies in these three classes
Wnt1 specific Wnt3a specific A B W n t 3 W n t 3 a W n t 1 W n t 2 W n t 1 0 b W n t 9 a W n t 7 b W n t 7 a W n t 6 W n t 1 0 a competed with antibodies in the same class but not antibodies in different classes (Fig. 3A) , suggesting that antibodies in the same class bind to the same or overlapping site of LRP6. (Fig. 3B) . One possible explanation of the results is that Wnt1-specific LRP6 antibodies (class A (Fig. S2) . To eliminate the contribution of endogenous LRP6, HEK293 cells were cotransfected with siRNA to LRP6 along with the relevant LRP5 deletion mutants and empty vector, a Wnt1-or Wnt3a-expression plasmid. The synergy between Wnt and a given LRP5 deletion mutant was measured by taking the ratio of STF activity induced by LRP5 deletion mutant and Wnt-expression plasmid over the STF activity induced by LRP5 deletion mutant and the empty vector. As seen in Fig. 3C, deletion of 
SOST is a secreted Wnt antagonist that binds to the extracellular domain of LRP5/6 (25, 26) . Missense mutations of LRP5, which are all clustered in propeller 1 of LRP5, are linked to high bonemass (HBM) diseases. How SOST deficiency increases bone density is not well-understood, although SOST proteins show reduced binding to LRP5 HBM mutants (25, 27) . We tested the ability of SOST to compete with various anti-LRP6 Fab fragments for binding to exogenously expressed LRP6. Here, we found that SOST blocked the binding of Wnt1 class-specific anti-LRP6 Fab fragments, but not other anti-LRP6 Fab fragments, to LRP6 (Fig.  3A) . Together with our finding that Wnt1-specific anti-LRP6 antibodies bind to propeller 1 of LRP6, these results suggest that SOST binds to propeller 1 of LRP6 and blocks the binding of Wnt proteins, consistent with the observation that all HBM mutations are clustered in propeller 1 of LRP5. Because SOST specifically competed with Wnt1 class-specific anti-LRP6 antibodies in the LRP6-binding assay, a prediction is that SOST would preferentially inhibit the signaling activity of the Wnt1-class proteins. Indeed, coexpression of SOST strongly inhibited Wnt1-and Wnt2-induced STF activation but slightly increased Wnt3-and Wnt3a-induced STF activation (Fig. 3D) .The enhancement of Wnt3-and Wnt3a-mediated signaling could result from dimerization of LRP6 (Discussion). As a control, we showed that coexpression of DKK1 inhibited the signaling activity of all Wnt proteins (Fig. 3D) . These data suggest that both Wnt1-class LRP6 antibodies and SOST bind to the first propeller of LRP6.
Bivalent LRP6 Antibodies Sensitize Cells to Wnt Signaling. The signaling activity of many membrane receptors is affected by dimerization or oligomerization. How dimerization affects the signaling activity of LRP6 has been controversial (7, 28) . The availability of antibodies capable of binding to endogenous LRP6 provided a unique opportunity to test whether dimerization of endogenous LRP6 affects Wnt/β-catenin signaling. We found that Wnt1-specific anti-LRP6 antibodies in the IgG format (A1-IgG, A2-IgG, and A3-IgG) strongly inhibited Wnt1-induced STF activity (Fig. 4A ) compared with the Fab counterparts (Fig. 1A) . In contrast, the Wnt1-specific anti-LRP6 antibodies markedly increased Wnt3a-induced STF activity (Fig. 4A ) and Wnt3a-induced phosphorylation of LRP6 (Fig. 4B) . Similarly, Wnt3a-specific anti-LRP6 antibodies in the IgG format (B1-IgG, B2-IgG, and B3-IgG) not only inhibited Wnt3a-induced STF activity but also increased Wnt1-induced STF activity (Fig. 4A) . The synergy between bivalent anti-LRP6 antibodies and the alternative class of Wnt proteins is fully consistent with the hypothesis that dimerization of LRP6 enhances Wnt signaling (7). In the absence of Wnt3a-conditioned medium, bivalent anti-LRP6 antibodies did not activate the STF reporter (Fig. S3) or increase phosphorylation of LRP6 (Fig. 4B) . Furthermore, combinations of Wnt1-and Wnt3a-specific anti-LRP6 IgGs completely blocked both Wnt1-and Wnt3a-induced STF activation (Fig. 4C) . These results suggest that bivalent LRP6 antibodies do not activate signaling by themselves and they only sensitize cells to Wnt signaling, possibly through dimerization of endogenous LRP6. Because autocrine Wnt signaling has been implicated in tumorigenesis, we tested whether LRP6 antibodies in the IgG format can inhibit Wnt signaling and tumor growth in vivo. A xenograft model was established by passaging primary MMTV-Wnt1 tumor in nude mice. To measure the effect of LRP6 antibodies on Wnt signaling in MMTV-Wnt1 tumors, tumor-bearing mice were treated with a single dose of 5 mg/kg A7-IgG, which is an affinity matured Wnt1-specific anti-LRP6 antibody derived from A1. Serum concentrations of the antibody as well as the mRNA expression of β-catenin target gene Axin2 were analyzed over a period of 2 wk. As seen in Fig. 5A , the terminal β-phase halflife of A7-IgG is about 108 h. Corresponding to the antibody injection, we observed a significant decrease of Axin2 mRNA expression in tumors, and Axin2 expression gradually recovered 1 wk after the antibody injection when the antibody level in serum decreased (Fig. 5A and Fig. S4A ). These results indicate that A7-IgG is able to suppress Wnt signaling in MMTV-Wnt1 xenografts and that this suppression is correlated with the antibody concentration in serum. To test the effect of anti-LRP6 antibodies on tumor growth, mice were treated with a Wnt1 classspecific LRP6 antibody (A7-IgG), Wnt3a class-specific LRP6 antibody (B2-IgG), or IgG control. We found that Wnt1 classspecific anti-LRP6 antibody induced tumor regression without causing body-weight loss, and Wnt3a class-specific anti-LRP6 antibody had no activity on MMTV-Wnt1 xenografts ( Fig. 5B and Fig. S4B ). We also tested these antibodies in an MMTVWnt3 xenograft model. Mice bearing established MMTV-Wnt3 tumor xenografts were treated with either IgG control or Wnt3a class-specific anti-LRP6 antibody (B2-IgG) or either Wnt1 classspecific anti-LRP6 antibody (A7-IgG) or IgG control. Wnt3a class-specific, but not Wnt1 class-specific, anti-LRP6 antibody inhibited the growth of MMTV-Wnt3 xenografts without inducing body-weight loss (Fig. 5C and Fig. S4C ). Together, our results show that Wnt1 or Wnt3a class-specific anti-LRP6 antibody specifically inhibits the growth of MMTV-Wnt1 or MMTVWnt3 xenografts. (Fig. 6A ). This biparatopic antibody (BpAb A7/B2) strongly inhibited both Wnt1-and Wnt3a-induced β-catenin signaling without showing any agonistic activity (Fig. 6B ).
Discussion
Misregulation of Wnt signaling has been linked to various human diseases. To modulate Wnt signaling in diseases, we have generated humanized agonistic and antagonistic anti-LRP6 antibodies and shown that antagonistic anti-LRP6 antibodies block Wnt-driven tumor growth in vivo. Using these anti-LRP6 antibodies, we have made several findings of Wnt biology. We have provided multiple lines of evidence indicating that different Wnt proteins require different propellers of LRP5/6 for signaling. We have also identified two classes of Wnt-potentiating anti-LRP6 antibodies that act through different mechanisms. Wnt proteins are thought to activate downstream signaling through binding to both Frz and LRP5/6 and promoting the formation of an active receptor-signaling complex. Using anti-LRP6 antibodies, we made the surprising finding that Wnt proteins can be divided into a Wnt1 class and a Wnt3a class, each requiring different propellers of LRP5/6 for signaling. This finding is further supported by a structural functional analysis of LRP5/6. During the preparation of this manuscript, it was published that Wnt3a binds to a fragment containing propeller 3 and 4 of LRP6, whereas Wnt9b binds to a fragment containing propeller 1 and 2 using an in vitro binding assay (29) . These results are fully consistent with our findings, and our work further shows the functional significance of the differential binding between Wnt proteins and LRP6 both in vitro and in vivo.
Our study has provided insights on the interplay of Wnt, LRP5/6, and SOST. The HBM mutations of LRP5 all reside in propeller 1 of LRP5. Recent studies suggest that SOST has reduced affinities to LRP5/6 HBM mutants (25, 27) . Our observation that SOST competes with Wnt1 class-specific anti-LRP6 antibodies for LRP6 binding (Fig. 3A) suggests that SOST blocks Wnt signaling by binding to propeller 1 of LRP5/6 and directly competing with the Wnt1-class proteins. This is consistent with our finding indicating that Wnt10b and Wnt7b, two proteins implicated in bone formation (30, 31) , belong to the Wnt1 class.
We have identified two anti-LRP6 antibodies that are agonistic in the monovalent Fab format. Epitope mapping and competition experiments suggest that both antibodies bind to a unique site within the propeller 3 of LRP6. Previous studies using LRP6 deletion mutants suggest that the extracellular domain might adopt an autoinhibitory conformation (28, 32, 33) . In LDLR, the intramolecular interaction between the LDLR domain and the β-propeller domain controls LDL binding and release from LDLR (34) . Whether an analogous intramolecular interaction exists in LRP5/6 and whether this interaction regulates Wnt signaling are currently unknown. It is possible that monovalent agonistic anti-LRP6 antibodies enhance Wnt signaling by relieving an inhibitory conformation of LRP6.
How the dimerization status of LRP5/6 regulates Wnt signaling has been controversial (7, 28) . Our observation that bivalent anti-LRP6 antibodies inhibiting one class of Wnt proteins sensitize cells to the other class supports the hypothesis that dimerization of endogenous LRP6 promotes Wnt signaling, possibly by increasing the avidity of various interactions involving LRP6. This is consistent with data indicating that Wnt treatment induces the formation of plasma membrane-associated LRP6 aggregates, likely promoted by self-oligomerization of Dishevelled (33) . Our discovery also raises the prospect of making even more potent Wnt sensitizers by generating multivalent anti-LRP5/6 antibodies.
Increased autocrine Wnt signaling has been associated with tumor development and progression, and therefore, antagonistic anti-LRP6 antibodies can potentially be used to treat cancer. Because the relevant Wnt proteins expressed in tumors are not well-defined, it would be advantageous to have a single molecule capable of inhibiting multiple Wnt ligands. This can be addressed with strategies to block signaling of all Wnt proteins without eliciting agonistic activities. In this study, we have generated a biparatopic anti-LRP6 antibody that blocks both Wnt1-and Wnt3a-mediated β-catenin signaling without showing agonistic activities (Fig. 6B) . The therapeutic potential of this antibody in cancer treatment will be explored in future studies.
In summary, our study has provided insights on how LRP5 and LRP6 functionally interact with Wnt proteins and known secreted Wnt modulators. Anti-LRP6 antibodies generated in this study provide us unique opportunities to specifically modulate Wnt/β-catenin signaling mediated by different Wnt proteins in various disease settings.
Materials and Methods
The HuCAL GOLD antibody library was used for selection of LRP6-specific antibodies. HEK293 cells were cultured in DMEM supplemented with 10% FCS and antibiotics. Detailed methods are described in SI Materials and Methods.
